Abbott Laboratories Inc. announced the start of the TRILUMINATE feasibility trial evaluating a minimally invasive clip-based Tricuspid Valve Repair System (TVRS) to treat tricuspid regurgitation that's based on the same technology as Abbott's established MitraClip, which treatsmitral valve regurgitation.
The tricuspid valve is the valve between the right ventricle and the right atrium, and tricuspid regurgitation leads to blood flowing backward into the right atrium, which can lead to heart failure, atrial fibrillation and eventually increase the risk of mortality. Like MitraClip, TVRS is a minimally invasive catheter-developed clip that simply clips two of the valve leaflets together
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?